Connect with us

Technology

NETRAMARK UNVEILS AI DRIVEN INSIGHTS FOR MAJOR DEPRESSIVE DISORDER AND SCHIZOPHRENIA AT ISCTM CONFERENCE

Published

1 year ago

on

TORONTO, March 5, 2025 /CNW/ – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, presented two significant studies at the International Society for CNS Clinical Trials and Methodology (ISCTM) conference, showcasing the power of advanced machine learning in major depressive disorder (MDD) and schizophrenia clinical trials.

Mathematically Augmented Machine Learning Redefines MDD Clinical Trial Insights

NetraMark’s first presentation, “Novel Machine Learning Approach Outperforms Traditional Approaches in Major Depressive Disorder Clinical Trials”, demonstrated how NetraAI Sub-Insight Learning enhances patient stratification in MDD clinical trials over traditional methods.

NetraAI was designed to address the challenges of modeling clinical trial data, where traditional Machine Learning (ML), including deep learning, often falls short. Built to identify optimal patient cohorts for future trials, NetraAI enhances established ML methods by uncovering key variable combinations. In this presentation, NetraMark applied NetraAI to the CAN-BIND trial on escitalopram response, demonstrating its ability to significantly improve industry-standard ML models, the study revealed:

NetraAI-driven patient subpopulation analysis led to a 28% increase in model accuracy compared to traditional ML approaches.Sensitivity improved by 31%, while specificity increased by 51%, reducing false-positive rates.NetraAI successfully identified key combinations of variables that refine inclusion/exclusion criteria for more efficient trial design.This is made possible through NetraAI’s ability to discover which patients can be explained and those that cannot.

NetraAI identifies and explains key variable combinations, offering deeper insights into drug and placebo response. When NetraAI-derived variables were fed to traditional ML methods, the resulting performance was significantly enhanced, as shown in the table below.

Traditional
Method

Accuracy of Traditional
Method Alone (%)

Accuracy of Traditional
Method using NetraAI
derived variables (%)

Improvement (%)

Logistic Regression

54.29

77.14

+22.85

XGBoost

65.71

91.43

+25.72

Random Forest

62.86

82.86

+20.00

SVM

60.00

100.00

+40.00

Neural Network

60.00

77.14

+17.14

“This advancement validates NetraAI’s ability to learn about complex clinical trial patient populations in a way that modern ML methods cannot, and this can translate to significantly improving clinical trial outcomes,” said Dr. Joseph Geraci, Chief Technology Officer and Chief Scientific Officer of NetraMark.

Advancing Schizophrenia Clinical Trials with AI-Driven Biomarker Discovery

NetraMark’s second presentation, “Predictive Biomarker Discovery in Schizophrenia Using Advanced Machine Learning to Decode Heterogeneity”, demonstrated NetraAI’s ability to learn from heterogeneous patient populations in schizophrenia trials. Using data from the CATIE schizophrenia trial, NetraAI identified clinically meaningful subpopulations that respond preferentially to olanzapine or perphenazine. Key findings include:

Patients with moderate to severe symptom burden and mild behavioral disturbances responded better to olanzapine.Patients with moderate negative symptoms, mild to moderate hallucinations, and paranoia showed improved response to perphenazine.This innovative Sub-Insight Learning approach overcomes traditional ML limitations by discovering high-effect size subpopulations that replicate across datasets, enabling better trial enrichment strategies.

“These findings represent a significant step toward precision psychiatry, as it allows us to demonstrate that our technology can produce robust models that replicate. Further, these models reduce trial failures and increase treatment efficacy by seeking to identify the right patients for the right therapies,” said Dr. Joseph Geraci.

Transforming the Future of CNS Clinical Trials

NetraMark’s AI-driven methodologies have the potential to transform the landscape of CNS clinical research by: Enhancing patient stratification for more targeted trials. Reducing placebo response and trial failures. Accelerating drug development by improving predictive modeling.

As the field moves toward precision medicine, NetraMark’s innovations offer pharmaceutical companies and researchers a powerful toolset to unlock deeper insights into psychiatric disorders and treatment responses.

About NetraAI
In contrast with other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) that can significantly increase the chances of a clinical trial success. Other AI methods lack these focus mechanisms and assign every patient to a class, even when this leads to “overfitting” which drowns out critical information that could have been used to improve a trial’s chance of success.

About NetraMark

NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR).

Forward-Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation including statements regarding the potential improvements and success arising from NetraAI and its ability to improve patient outcomes, the identification of effective treatments, operational results and the design clinical trials, which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR at www.sedarplus.ca including our Management’s Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE NetraMark Holdings Inc.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Paid High School Internships Double College Completion Rates, Genesys Works Data Shows

Published

2 seconds ago

on

July 21, 2026

By

The national nonprofit’s 2025 Annual Impact Report finds 93% of participants — high schoolers placed in paid, yearlong internships — enroll in college, and 73% of surveyed alumni go on to out-earn at least one parent

HOUSTON, July 21, 2026 /PRNewswire/ — At a moment when AI is reshaping entry-level hiring and employers are questioning traditional talent pipelines, new data from Genesys Works makes the case that early professional experience changes the trajectory of a young person’s life. The national nonprofit today released its 2025 Annual Impact Report. Stronger Together, that highlights short- and long-term outcomes for Genesys Works alumni.

In 2025, Genesys Works served 2,161 students and expanded its footprint with the launch of its newest site in Nashville. Its proven model begins with eight weeks of professional skills training during the summer, followed by a paid yearlong internship with a top employer. Students collectively earned $10.9 million in wages and $2.2 million in scholarships.

Of the Class of 2025, 93% of Genesys Works participants enrolled in college, nearly double the national average for first-generation students, according to data from the National Student Clearinghouse (NSC). Alumni pursuing bachelor’s degrees finish within six years at 2.4 times the rate of their peers, and 26% earn degrees in STEM compared to 9.1% of graduates from low-income high schools, based on data from NSC.

The gains compound over time. Among alumni seven or more years post- program, the average income is $67,000, 73% of surveyed alumni report earning more than at least one parent, and 20% own a home. By enabling students to build the skills, experience, and professional networks needed to thrive, the program continues to deliver strong outcomes in college completion, career success, and economic mobility.

“As AI redraws the entry-level job market, young people with the fewest connections stand to lose the most. At Genesys Works, we’re in the business of unlocking human potential — enabling young people to forge those connections and preparing them for meaningful careers while helping employers build the workforce they’ll need,” said Byron V. Garrett, CEO of Genesys Works. “These results show what happens when talent meets opportunity.”

Employers also recognize the program’s value. Ninety-two percent of internship managers report interns meet or exceed expectations, and 99% recommend Genesys Works.

The full 2025 Annual Impact Report is available at genesysworks.org.

About Genesys Works 
Genesys Works provides pathways to career success for high school students in underserved communities. Our program consists of 8weeks of technical and professional skills training, paid year-long corporate internships, college and career coaching, and long-term alumni support to move individuals out of economic inequality and into professional careers. Founded in 2002, Genesys Works now serves thousands of students annually in Chicago, Houston, Jacksonville, Minneapolis/St. Paul, Nashville, New York City, the San Francisco Bay Area, Tulsa, and Washington’s National Capital Region. To learn more, visit genesysworks.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/paid-high-school-internships-double-college-completion-rates-genesys-works-data-shows-302830148.html

SOURCE Genesys Works

Continue Reading

Technology

Observability Tools and Platforms Market worth $22.99 billion by 2031 – Report by MarketsandMarkets™

Published

4 seconds ago

on

July 21, 2026

By

DELRAY BEACH, Fla., July 21, 2026 /PRNewswire/ — According to MarketsandMarkets™, the global Observability Tools & Platforms Market size will grow to USD 22.99 billion by 2031 from USD 11.91 billion in 2026, at a CAGR of 14.1% during the forecast period.

Browse 250 market data Tables and 250 Figures spread through 320 Pages and in-depth TOC on ‘Observability Tools & Platforms Market – Global Forecast to 2031’

Observability Tools & Platforms Market Size & Forecast:

Market Size Available for Years: 2021–20312025 Market Size: USD 10.47 billion2026 Market Size: USD 11.91 billion2031 Projected Market Size: USD 22.99 billionCAGR (2026–2031): 14.1%

Observability Tools & Platforms Market Trends & Insights:

The Observability Tools & Platforms Market is witnessing rapid growth as enterprises accelerate cloud-native adoption, distributed application development, and AI-driven IT operations.By offering, services are projected to register the highest CAGR of 17.1% during the forecast period, driven by growing demand for implementation, managed observability, and platform optimization expertise.By solution, distributed tracing is projected to register the highest CAGR of 18.2% during the forecast period, driven by increasing adoption of microservices and cloud-native architectures.By telemetry type, events, profiles, and traces are projected to register the highest CAGR of 13.5% during the forecast period, driven by AI-powered diagnostics and deep application insights.North America to lead the market

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=69804486

The market is expanding as enterprises operate increasingly distributed applications across cloud-native, hybrid-cloud, and on-premises environments. Growing Kubernetes adoption, microservices architectures, and DevOps practices generate larger volumes of logs, metrics, traces, events, and profiles requiring unified analysis. Organizations are adopting observability platforms to correlate telemetry, identify performance degradation, and accelerate root-cause analysis across complex technology stacks. OpenTelemetry adoption is improving instrumentation consistency, while artificial intelligence supports anomaly detection, incident investigation, and operational automation. These capabilities strengthen digital resilience, reduce service disruptions, and support dependable application experiences across global industries worldwide.

By telemetry type, the metrics segment to hold the largest market size.

By telemetry type, the metrics segment is expected to hold the largest Observability Tools & Platforms Market share. Applications, cloud infrastructure, containers, databases, networks, and digital services continuously generate numerical performance indicators supporting real-time operational monitoring. Enterprises rely on metrics for dashboards, alerting, capacity planning, anomaly detection, service-level monitoring, and infrastructure optimization. Expanding cloud-native deployments and Kubernetes environments sustain demand for scalable metrics collection and analysis. Integration with logs, traces, and events further strengthens metrics as a foundational source for monitoring system health and application performance.

Request for Proposal @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=69804486

By solution, the distributed tracing segment is expected to register the highest growth rate during the forecast period.

By solution, the distributed tracing segment is expected to register the highest growth rate in the Observability Tools & Platforms Market during the forecast period. Expanding microservices, Kubernetes, serverless computing, and distributed cloud architectures have increased the complexity of tracking requests across interconnected services. Distributed tracing enables development and operations teams to identify latency sources, service dependencies, and transaction failures across application environments. Growing OpenTelemetry adoption is simplifying standardized trace collection, while AI-assisted analytics improve anomaly detection and root-cause investigation. These capabilities are accelerating adoption across cloud-native enterprises requiring deeper application visibility.

North America to lead the market

North America is expected to remain the largest regional market for the Observability Tools & Platforms Market, supported by widespread cloud-native adoption, mature digital infrastructure, and strong enterprise technology investments. The region hosts leading hyperscale cloud providers, software vendors, and digital-native enterprises operating large-scale distributed applications requiring continuous observability across hybrid and multi-cloud environments. Organizations increasingly deploy application performance monitoring, distributed tracing, infrastructure monitoring, and AI-driven operational analytics to improve service reliability and accelerate incident resolution. OpenTelemetry adoption continues expanding across enterprises, enabling standardized telemetry collection and interoperability between observability platforms. In June 2026, Datadog acquired Adaptive ML to strengthen AI-powered autonomous operations by combining specialized artificial intelligence models with production observability data, reinforcing innovation across cloud operations. Growing investments in Kubernetes, DevOps, Site Reliability Engineering, cybersecurity, and enterprise application modernization continue generating sustained demand for unified observability platforms capable of delivering real-time operational intelligence, automated root-cause analysis, and proactive performance optimization across increasingly complex digital ecosystems.

Request Pricing @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=69804486

Top Companies in Observability Tools & Platforms Market:

The Top Companies in Observability Tools & Platforms Market are Datadog (US), Dynatrace (US), Splunk (US), New Relic (US), Elastic (US), IBM (US), Grafana Labs (US), SolarWinds (US), ServiceNow (US), Microsoft (US), Oracle (US), LogicMonitor (US), Coralogix (Israel), Chronosphere (US), ScienceLogic (US), Honeycomb (US), Sentry (US), Acceldata (US), Kentik (US), and Arize AI (US).

Browse Adjacent Markets: Software and Services Market Research Reports & Consulting

Related Market Reports:

Cloud Computing Market by Service Model (IaaS (Compute, Storage, Networking), PaaS (Application Development & Integration, Database & Data, Analytics & Reporting), SaaS (CRM, SCM, Collaboration & Productivity)), Impact of AI – Global Forecast to 2030

Enterprise Monitoring Market by Platform (Infrastructure, Application Performance, Security, Digital Experience, Workforce Operation), Digital Experience Platform (Synthetics, Real User Experience, Web Performance) – Global Forecast to 2029

About MarketsandMarkets™  

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/observability-tools-and-platforms.asp

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/observability-tools-and-platforms-market-worth-22-99-billion-by-2031—report-by-marketsandmarkets-302830518.html

SOURCE MarketsandMarkets

Continue Reading

Technology

Prezent Vivo 1.0 accelerates AI-native med comms with AI-generated posters and fixed-price scientific delivery

Published

6 seconds ago

on

July 21, 2026

By

Prezent Vivo 1.0 features a reimagined AI-native platform with an interactive content studio, AI-generated scientific posters, overnight editorial services, and Fixed-Price Projects that help Medical Affairs and Commercial teams create high-quality communications faster, with expert oversight, 24 to 72-hour delivery, and more than 50% cost savings.

PALO ALTO, Calif., July 21, 2026 /PRNewswire/ — Prezent Vivo, the communications platform trusted by more than 150 Life Sciences companies, including 45 of the world’s top 50 BioPharma organizations, today launched Prezent Vivo 1.0, a reimagined AI-native platform featuring an interactive content studio, AI-generated scientific posters, overnight editorial services, and Fixed-Price Projects that help Medical Affairs and Commercial teams create high-quality communications faster, with expert oversight and lower costs.

An Integrated Experience for Life Sciences Communication

Built around the way life sciences teams work, Prezent Vivo 1.0 combines purpose-built AI with expert medical communications services in a single platform. Medical Affairs and Commercial teams can create, manage, and scale communications by generating first drafts with conversational AI, creating congress-ready scientific posters, or engaging Prezent’s experts for high-stakes projects, moving seamlessly between self-serve AI and expert-managed services as needed.

“Scientific breakthroughs only matter when they’re communicated effectively,” said Rajat Mishra, CEO and Co-Founder of Prezent. “Prezent Vivo 1.0 brings AI and human expertise together to help Life Sciences teams move from discovery to better patient outcomes, faster.”

The New AI-Native Platform

At the core of Prezent Vivo 1.0 is a reimagined AI-native platform. The interactive content studio combines conversational AI, expert services, and seamless access to enterprise and scientific data sources, including PubMed, Veeva, Microsoft Copilot, and 25+ other integrations.

Astrid, Prezent’s AI agent for life sciences, transforms scientific content into high-quality communications while incorporating brand compliance, regulatory language, and clinical evidence structures from the very first draft.

AI-Generated Scientific Posters

One of the key additions to Prezent Vivo 1.0 is AI-generated scientific posters. Astrid transforms abstracts, publications, clinical study reports, spreadsheets, and other scientific source materials into congress-ready, publication-quality posters in minutes. Supporting more than 13 languages, Prezent Vivo 1.0 helps global Medical Affairs and Commercial teams accelerate congress preparation while maintaining scientific rigor.

Fixed-Price Projects Deliver Expert Communications at AI Speed

Prezent Vivo 1.0 also introduced Fixed-Price Projects, a fully managed service that combines AI-native speed with expert scientific oversight to deliver agency-quality medical communications in 24 to 72 hours at more than 50% lower cost than traditional agency models.

Prezent’s customers can share their objectives and source materials to Astrid and the platform then creates an initial draft, while Prezent’s Presentation Engineers and medical communications experts refine the narrative, validate the science, and ensure every deliverable meets the highest standards of accuracy, compliance, and quality.

Prezent Vivo 1.0 Fixed Price Projects launches with three specialized offerings:

Competitive Intelligence 360: Provides pre-congress planning, overnight congress coverage, post-event synthesis within 24 hours, and ongoing competitive monitoring.AdBoard Insights: Accelerates advisory board reporting with expert-validated showreels and moderator guides before meetings, executive summaries within 24 hours, and strategic reports within 72 hours.Scientific Posters: Transforms accepted abstracts into congress-ready, print-ready posters within 72 hours, with optional digital ePosters, HCP presentations, and plain-language summaries.

Overnight Editorial Services

Prezent Vivo 1.0 also expanded managed services with Overnight Editorial Services. In addition to Prezent’s design excellence, expert editors now review presentations overnight for copy precision, helping Life Sciences teams improve clarity, consistency, and scientific accuracy while meeting demanding timelines.

Our customers didn’t ask us for another AI feature,” said Deepti Juturu, Co-Founder and Chief Customer Officer at Prezent Vivo. “Prezent Vivo’s customers wanted one partner that could support every type of communication their teams create. Whether they’re generating a scientific poster in minutes or outsourcing an advisory board project, they expect the same speed, scientific precision, compliance, and quality. Prezent Vivo 1.0 release delivers exactly that.”

Built for the Way Life Sciences Teams Work

Life Sciences teams are under increasing pressure to create effective communications and respond faster to scientific developments. While general-purpose AI offers speed, it often lacks the scientific depth required for regulated communications, and traditional agencies can be slower and more costly.

Prezent Vivo combines purpose-built AI with expert medical communications services, enabling teams to move seamlessly between AI-powered content creation and expert support based on the needs of each project.

“Prezent Vivo 1.0 gives Life Sciences teams the flexibility to work the way they need, with AI, experts, or a combination of both, helping them reduce costs without compromising scientific quality.” – Francine Carrick, President, Prezent Vivo

About Prezent

Prezent is the only Life Sciences communications platform that combines purpose-built AI with human expertise to deliver fast, cost-effective, scientifically precise, and compliant communications at scale. Headquartered in Palo Alto, California, Prezent serves more than 150 Life Sciences companies, including 45 of the world’s top 50 BioPharma organizations. Through Prezent Vivo, the company helps Medical Affairs and Commercial teams create high-quality communications faster across the entire product lifecycle.

View original content to download multimedia:https://www.prnewswire.com/news-releases/prezent-vivo-1-0-accelerates-ai-native-med-comms-with-ai-generated-posters-and-fixed-price-scientific-delivery-302830965.html

SOURCE Prezent

Continue Reading

Trending